April 3, 2017 / 12:57 PM / 19 days ago

BRIEF-Nanobiotix Says First Phase I Trial With NBTXR3 In Pancreatic Cancer Is Safe To Proceed Per US FDA

May 6 (Reuters) - Nanobiotix SA:

* NANOBIOTIX ANNOUNCES FIRST PHASE I TRIAL WITH NBTXR3 IN PANCREATIC CANCER IS SAFE TO PROCEED PER US FDAec

* TRIAL WILL RECRUIT UP TO APPROXIMATELY 24 PATIENTS WITH A PLANNED ENROLLMENT PERIOD OF 18 MONTHS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below